Progression of pentosan polysulfate sodium maculopathy following discontinuation
DOI:
https://doi.org/10.62856/djcro.v1i1.23Keywords:
Maculopathy, Retina, Drug Toxicity, Pentosan polysulfateAbstract
Examination of a 69-year-old woman with a family history of age-related macular degeneration (AMD) revealed bilateral macular atrophy with surrounding deposits evident on fundus autofluorescence (FAF). The extent of macular atrophy in this 69-year-old, lack of typical drusen, and FAF pattern did not support a diagnosis of AMD. Her clinical presentation was consistent with pentosan polysulfate sodium (PPS) maculopathy. Further questioning revealed that she had been taking 400 mg of PPS daily for 7 years (cumulative dose ~1000g) but had stopped 2 years ago. Review of available previous images demonstrated continued progression of the maculopathy after discontinuation of PPS. FAF demonstrated atrophy in both eyes 18 months after PPS discontinuation, as well as its progression over the subsequent 6 months. Her clinical presentation was consistent with PPS maculopathy, with evidence of progressive atrophy despite PPS discontinuation 2 years earlier.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Contributor assigns to Duke, during the full term of copyright and any extensions or renewals, all copyright in and to the Manuscript, and all rights therein, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Manuscript in whole or in part in electronic editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. "Manuscript" means the article submitted by the Contributor for publication in the DJCRO (including any embedded rich media) and all subsequent versions. The definition of Manuscript does not extend to any supporting information submitted with or referred to in the Manuscript ("Supporting Information"). To the extent that any Supporting Information is submitted to the DJCRO, Duke is granted a perpetual, non-exclusive license to publish, republish, transmit, sell, distribute and otherwise use this Supporting Information in whole or in part in electronic and print editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. If the Manuscript was shared as a preprint, the Contributor grants to Duke exclusivity as to any rights retained by the Contributor in the preprint.
Reproduction, posting, transmission or other distribution or use of the final Manuscript in whole or in part in any medium by the Contributor as permitted by this Agreement requires a citation to the DJCRO suitable in form and content as follows: (Contributor(s), Title of Manuscript, Journal Title, Journal Volume, Copyright© [year], Digital Object Identifier [DOI] link to final Manuscript). Links to the final article on the DJCRO website are also encouraged where appropriate.
